Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCE2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,901
Award facts
- Contract value 100% obligated
- $34,900.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $34,900.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order, awarded on January 20, 2026, with an ultimate completion date of February 10, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a discrete purchase under DMS Pharmaceutical Group's broader relationship with the Defense Logistics Agency's pharmaceutical supply operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036. The PPV-G GEN V program, part of the Defense Logistics Agency's $30.3 billion pharmaceutical acquisition strategy, authorizes firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across multiple therapeutic categories, including oncology treatments, biologics, vaccines, and specialty pharmaceuticals, positions the company as a critical supplier within the federal military pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FSCE2?
SPE2DR26FSCE2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FSCE2 worth?
The government has obligated $34,901 on SPE2DR26FSCE2.
Is contract SPE2DR26FSCE2 an order under another contract?
Yes. SPE2DR26FSCE2 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCE2 competed?
The extent of competition for SPE2DR26FSCE2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award